metaPreg - Lurasidone during pregnancy

Lurasidone updated on 06-10-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	1.32 [0.38, 4.60]	-	1 study	19	137	not evaluable	ROB	-
Major congenital malformations	1.32 [0.38, 4.60]	-	1 study	19	137	not evaluable	ROB	-
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	0.44 [0.14, 1.36]	-	1 study	46	25	not evaluable	ROB	-
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Caesarean	0.92 [0.37, 2.29]	-	1 study	55	25	not evaluable	ROB	-
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Neonatal medical care	0.84 [0.31, 2.26]	-	1 study	44	25	not evaluable	ROB	-
Withdrawal syndrome / Neonatal abstinence syndrome / Poor neonatal adaptation	0.34 [0.04, 2.67]	-	1 study	17	24	not evaluable	ROB	-
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Intrauterine deaths (as a whole or unspecified)	0.64 [0.03, 12.29]	-	1 study	4	24	not evaluable	ROB	-
Hide endpoints reported in only one study ...